Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Respect the Dormant Beast: Tumor Board
Description
The tumor board session, led by Dr. Ruiz, involved presenting two challenging cases for discussion among a panel of experts including Dr. Werthrich, a radiation oncologist, Dr. Silk, a medical oncologist, and Dr. Patel, a Mohs surgeon. The session featured a hybrid format combining case presentations and educational components. The first case discussed an 89-year-old male with a moderately differentiated squamous cell carcinoma; his gene expression profiling (GEP) test indicated an 80% chance of metastasis-free survival. The case raised questions about treatment options, as the referring dermatologist was uncertain of the next steps. The second case involved a 71-year-old male renal transplant recipient with an infiltrative tumor, which after a GEP test revealed a 93% risk, prompted concerns about the staging and actual prognosis. Both cases were analyzed for their risk assessments and how GEP informs treatment decisions. The discussion aimed to clarify the most effective approaches for managing these complex patient scenarios.
View moreConclusions
- Gene expression profiling can inform treatment decisions for patients with different types of tumor characteristics.
- For patients with low-risk features, like the 89-year-old male, surveillance may be appropriate given his favorable gene expression profile.
- The 71-year-old renal transplant recipient with high-risk features may require more aggressive management due to his poorer prognosis indicated by gene expression profiling.
- Understanding the tumor's stage and biology is critical in determining the course of treatment and surveillance strategies.
- Adjuvant and neoadjuvant therapies need to be tailored based on individual risk assessments derived from gene expression data.